A total of 46,803 HER2-positive breast cancer patients diagnosed from 2010 to 2016 were identified, of which 32,919 (70.3%) were HR + /HER2 + and 13,884 (29.7%) were HR-/HER2 + subtype. Here, HR is linked to breast cancer.